Asplenia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:19:52 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Asplenia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Pneumococcal Vaccine Response in Patients Without a Spleen: Comparing Vaccination Before and After Spleen Removal Using PCV20 and PCV21 https://clinicaltrials.eu/trial/study-of-pneumococcal-vaccine-response-in-patients-without-a-spleen-comparing-vaccination-before-and-after-spleen-removal-using-pcv20-and-pcv21/ Wed, 29 Apr 2026 15:07:27 +0000 https://clinicaltrials.eu/trial/study-of-pneumococcal-vaccine-response-in-patients-without-a-spleen-comparing-vaccination-before-and-after-spleen-removal-using-pcv20-and-pcv21/ This clinical trial studies immune responses to pneumococcal vaccines in people without a spleen (a condition called asplenia). The study compares two vaccines: Prevenar 20 and CAPVAXIVE, which are designed to protect against different strains of bacteria that can cause serious infections. The purpose is to understand how the timing of vaccination – either before or after surgical removal of the spleen – affects the body’s immune response to these vaccines.

The study involves adults who either have already had their spleen removed or are scheduled for spleen removal surgery. Participants will receive two different vaccines: first Prevenar 20, followed by CAPVAXIVE at least 12 months later. Both vaccines are given as a single injection into the muscle. The main focus is on measuring how well the immune system responds to the vaccines when given at different times relative to spleen removal.

The research team will collect blood samples to measure antibody levels and immune cell responses at various points during the study. This will help determine the best timing for vaccination in patients without a spleen. The study will continue for approximately two years, comparing immune responses between patients vaccinated before spleen removal, after spleen removal, and healthy individuals who still have their spleen.

]]> Study on the Safety and Immune Response of Meningococcal B Vaccines in Adults with Asplenia: Bexsero, Trumenba, and a Drug Combination https://clinicaltrials.eu/trial/study-on-the-safety-and-immune-response-of-meningococcal-b-vaccines-in-adults-with-asplenia-bexsero-trumenba-and-a-drug-combination/ Wed, 29 Apr 2026 15:00:49 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-immune-response-of-meningococcal-b-vaccines-in-adults-with-asplenia-bexsero-trumenba-and-a-drug-combination/ This clinical trial is focused on studying the effectiveness and safety of three different vaccine strategies for preventing infections caused by the bacteria *Neisseria meningitidis* group B in patients with *asplenia*. *Asplenia* is a condition where a person does not have a functioning spleen, which is an organ that helps fight infections. The vaccines being studied are *Bexsero* and *Trumenba*, both of which are designed to protect against *meningococcal* group B infections. *Bexsero* contains several components produced using recombinant DNA technology, which means they are made by combining DNA from different sources to create a new set of genes. *Trumenba* includes proteins from two subfamilies of the *Neisseria meningitidis* group B bacteria.

The purpose of the study is to assess how well these vaccines work in generating an immune response in adults with *asplenia*. Participants will receive the vaccines as injections into the muscle. The study will last for several months, with the main evaluation occurring one month after the completion of the vaccine series. During this time, researchers will monitor the participants to see how their immune systems respond to the vaccines and to ensure their safety.

Participants in the study will be adults who have been without a functioning spleen for at least two weeks. The study will help determine the best vaccination strategy for protecting people with *asplenia* from *meningococcal* group B infections, which can be serious and life-threatening. The results of this study could provide valuable information for improving the health and safety of individuals with this condition.

]]>